
    
      Participants are randomized in a ratio of 1:1 into 20 µg recombinant hepatitis B vaccine
      group or 60µg recombinant hepatitis B vaccine group. The 20 µg group will receive three
      intramuscular injections of the 20 µg recombinant hepatitis B vaccine, while the 60 µg group
      will receive three intramuscular injections of the 60 µg dose at months 0, 1 and 6,
      respectively. HBsAg and anti-HBs will be tested during the study period. Adverse reactions
      will be recorded after vaccination.
    
  